CHRS: Don’t Miss Coherus’ Key Stock Offering Update!

Recent Stock Offering & Strategic Overview

Coherus BioSciences (now Coherus Oncology, NASDAQ: CHRS) recently executed a significant equity raise to fund its refocused oncology strategy. On February 12, 2026, Coherus announced a public offering of 28.6 million shares at $1.75 per share, raising approximately $50.1 million in gross proceeds (www.globenewswire.com). This dilutive stock offering is a key update for investors, as it bolsters Coherus’ cash reserves for drug development. It also highlights the stock’s decline – by contrast, Coherus raised a similar ~$50 million in May 2023 at $4.25 per share (investors.coherus.com), underlining a steep drop in equity value over the past three years. The latest offering aligns with Coherus’ strategic transformation: over 2024–25 the company divested all its legacy biosimilar franchises to focus exclusively on its immuno-oncology pipeline (www.fiercepharma.com). Proceeds from those asset sales have been used to strengthen the balance sheet and fund Coherus’ pivot “all-in” toward its novel cancer drug LOQTORZI® (toripalimab) and related pipeline programs (www.fiercepharma.com).

Dividend Policy & Yield

Coherus does not pay any dividend on its common stock. In fact, the company explicitly states it has never declared or paid cash dividends and does not anticipate doing so for the foreseeable future (investors.coherus.com). This policy is typical for clinical-stage biotech companies that reinvest any would-be profits into R&D. With no dividends, Coherus’ dividend yield is effectively 0% (www.macrotrends.net). Metrics like Funds From Operations (FFO) or Adjusted FFO – relevant for REITs – do not apply to Coherus’ business model, as the company does not generate stable operating cash flows or distributable income. Coherus instead retains capital (or raises new capital) to finance drug development, rather than returning cash to shareholders (investors.coherus.com).

Leverage and Debt Maturities

Coherus carried significant debt in the form of convertible notes, but it has aggressively repaired its leverage in the past year. The company had $230 million of 1.500% Convertible Senior Notes maturing in April 2026 (investors.coherus.com). In late 2024, management struck a transformative deal to address this overhang: Coherus sold its UDENYCA® (pegfilgrastim) biosimilar franchise to Intas Pharmaceuticals for up to $558.4 million (including a $483.4 million cash upfront payment) (investors.coherus.com) (investors.coherus.com). A portion of these proceeds is being used to fully repay the entire $230 million of convertible notes due 2026 (investors.coherus.com), as well as to buy out $49.1 million of royalty obligations related to UDENYCA (investors.coherus.com). This effectively eliminates Coherus’ long-term debt, markedly deleveraging the balance sheet. The Intas divestiture followed two earlier 2024 asset sales: Coherus sold its CIMERLI® ophthalmology (biosimilar Lucentis) business to Sandoz for a $170 million all-cash payment (investors.coherus.com), and divested its YUSIMRY™ Humira biosimilar rights for $40 million in cash to Meitheal Pharmaceuticals (investors.coherus.com). Together, these transactions generated hundreds of millions in liquidity, enabling Coherus to retire debt and avoid near-term maturities. As of early 2025, with the convertible notes being repurchased, Coherus has no major debt maturities looming – a dramatic improvement from the prior April 2026 deadline (investors.coherus.com).

Liquidity and Coverage

Following the asset sales and stock offerings, Coherus’ liquidity position is greatly strengthened. As of Q3 2025 the company reported $191.7 million in cash, equivalents and marketable securities on hand (www.globenewswire.com) – up from $126 million at year-end 2024 (www.globenewswire.com). The recent $50 million equity raise in Feb 2026 will further bolster cash reserves. This liquidity is crucial given Coherus’ ongoing cash burn from R&D and commercialization of LOQTORZI. The elimination of the 1.5% convertible debt also reduces interest expense obligations going forward. Interest coverage (EBIT/interest) had been poor – Coherus has consistently operated at a net loss, so operating earnings have not covered interest costs. For example, Coherus lost $44.5 million from continuing operations in Q3 2025 (www.globenewswire.com), far outstripping its modest quarterly interest expense. Now, with debt largely gone, interest payments are negligible. However, coverage of overall expenses remains a concern: the company must fund R&D, marketing, and overhead from its cash reserves and any incoming revenue. Coherus’ strategy to cover these needs has been reliance on external financing – through asset divestitures and stock offerings – rather than internal cash generation. The recent deals provided non-dilutive cash infusions, but going forward, shareholder dilution (such as the 2026 equity issue) may recur if heavy cash outflows persist. In sum, Coherus has ensured near-term liquidity (cash ~$200+ million post-offering) and removed its debt burden, but it continues to consume cash for operations, meaning investors must monitor its cash runway closely.

Valuation and Comparables

Traditional valuation metrics for CHRS are complicated by the company’s transition and lack of earnings. Coherus’ earnings per share are negative (e.g. –$0.38 EPS from continuing ops in Q3 2025 (www.globenewswire.com)), so P/E ratios are not meaningful. Price-to-cash-flow is similarly not applicable given negative operating cash flow. On a revenue basis, Coherus’ valuation has swung from seemingly cheap to elevated, reflecting the loss of its biosimilar sales. In FY 2023, Coherus booked $257.2 million in net revenue (investors.coherus.com) from its diverse product portfolio, which implied a low trailing Price/Sales ratio at the time. However, after divesting those revenue streams, quarterly sales plummeted – Q3 2025 revenue was only $11.6 million (down from $70.8 million in Q3 2024) (www.nasdaq.com), solely from its nascent oncology product. Consequently, forward P/S has jumped (the stock’s market capitalization is a few hundred million vs. a likely <$50 million annualized sales run-rate post-divestitures). On the other hand, Coherus’ enterprise value (EV) is very low relative to its assets – with roughly $192 million in cash on hand (www.globenewswire.com) and minimal debt, the company’s EV is only on the order of tens of millions. At the current share price around $1–2, Coherus’ market cap (~$200–$300 million) is only slightly above its cash balance, implying the pipeline is being valued at near-zero by the market. This could suggest upside if the pipeline succeeds (the stock might be trading near “cash value”), but it also reflects investor skepticism. Comparable companies in biotech with a single approved drug and early-stage pipeline often trade on expectations of future clinical successes rather than on present financials. In Coherus’ case, any valuation upside likely hinges on the commercial ramp of LOQTORZI and positive trial data for its pipeline candidates, rather than on multiples of current earnings or book value.

Risks and Red Flags

Coherus presents several risk factors and red flags that investors should note:

– Lack of Profitability: Coherus has a history of substantial net losses and does not expect to become profitable in the near future (investors.coherus.com). The company’s operations are dependent on external funding and it may never achieve sustained profitability if its drug development efforts fall short. This ongoing unprofitability increases the risk of future dilution or debt if cash reserves dwindle.

– Single-Product Reliance: After selling off its biosimilar portfolio, Coherus is now heavily reliant on one commercial product, LOQTORZI® (toripalimab), a PD-1 immunotherapy for nasopharyngeal carcinoma. LOQTORZI faces competition from well-established PD-1 drugs in oncology and is approved in a relatively narrow indication currently. If LOQTORZI sales underperform or if broader label expansions fail, Coherus will have no other major revenue source. The company is essentially “all-in” on LOQTORZI and its few pipeline candidates (www.fiercepharma.com), which heightens business risk.

– Pipeline and Regulatory Risk: Coherus’ pipeline (e.g. its IL-27 antagonist casdozokitug and CCR8 antibody CHS-114) is in mid-stage trials (www.globenewswire.com) (www.globenewswire.com). There is significant clinical and regulatory risk – these experimental drugs may not demonstrate sufficient efficacy or safety to gain approval. Setbacks in trials could derail Coherus’ long-term growth plans. Moreover, developing novel oncology drugs is costly and time-consuming, and success is far from guaranteed.

– High Cash Burn & Dilution: The company’s R&D and commercialization expenses remain high (Coherus spent $27.3 million on R&D in Q3 2025 alone (www.globenewswire.com), plus SG&A for its commercial team). Even after the asset sale windfall, Coherus burned a large portion of the cash: it reported a $136.8 million net loss from continuing ops in the first nine months of 2025 (www.globenewswire.com). This high cash burn means Coherus may need additional capital before achieving self-sustaining cash flow. The February 2026 equity raise signals ongoing funding needs. Existing shareholders have been significantly diluted – note the share count has risen with offerings (e.g. 11.7 million new shares in 2023 (investors.coherus.com) and now 28.6 million in 2026 (www.globenewswire.com)). Future financing rounds (equity or debt) could further dilute equity or burden the company if not done judiciously.

– Uncertain Market Reception: Coherus’ newly focused business model carries market acceptance risk. Investors have markedly sold down the stock – the share price has dropped roughly 60%+ from 2023 levels, as evidenced by the much lower pricing of the latest stock offering compared to a similar 2023 offering (investors.coherus.com) (www.globenewswire.com). This weak stock performance indicates doubts about Coherus’ strategy or execution. If LOQTORZI uptake or clinical results disappoint, the stock could face further declines. Conversely, it may take significant positive news to regain investor confidence given the recent history.

Open Questions & Outlook

Looking ahead, several open questions will determine Coherus’ fate and whether the stock represents an opportunity or a value trap:

– Can LOQTORZI Achieve Broader Success? LOQTORZI (toripalimab) is currently approved for a niche cancer (recurrent/metastatic nasopharyngeal carcinoma). Coherus’ strategy is to expand LOQTORZI into additional indications and combinations (www.globenewswire.com). A key question is whether ongoing trials (e.g. in lung, liver, or other cancers) will enable LOQTORZI to compete against entrenched immunotherapies like Keytruda® and Opdivo®. The commercial traction of LOQTORZI in the U.S. is still unproven – its net revenue was only $11 million in Q3 2025 (www.globenewswire.com). Investors will be watching for sales growth in 2026 and beyond. Successful indication expansions or positive comparative data could transform LOQTORZI into a meaningful revenue driver, while weak uptake would severely limit Coherus’ near-term prospects.

– Will the Pipeline Deliver (or Be Partnered)? Coherus now touts an “innovative immuno-oncology pipeline” including casdozokitug (IL-27 antibody) and CHS-114 (CCR8 antibody) in Phase 1/2 studies (investors.coherus.com) (investors.coherus.com). These are high-risk, early-stage assets. Open questions include: Can Coherus advance them through proof-of-concept trials, and will the clinical data be compelling? The company may seek partnerships or licensing deals to share development costs – any such collaborations (or lack thereof) will signal confidence in the science. The outcome of these trials will likely define Coherus’ long-term value, but results are 1–2+ years out. Until then, the pipeline’s potential is a wildcard that the market currently assigns little value to.

– Is the Cash Runway Sufficient? After the Udenyca sale and the recent equity raise, Coherus has a decent cash cushion (on the order of $200–250 million between cash on hand (www.globenewswire.com) and the new $50M proceeds). However, with annualized losses well over $100 million (www.globenewswire.com), this runway might cover roughly 1–2 years of operations absent a big change in revenues or expenses. The company will need to manage its spending carefully or grow LOQTORZI sales substantially to avoid another capital raise. An open question is when Coherus might reach a self-sustaining financial position. Management has indicated they do not foresee profitability in the near term (investors.coherus.com). Investors should monitor quarterly cash burn and any guidance on how long current funds will last. If cash is projected to dwindle before profitability or a partnership inflection, further dilution or financing could be on the horizon.

– How Will Asset Divestitures Impact Value? Coherus’ 2024 divestitures provided vital cash, but they also mean the company let go of steady revenue streams (biosimilars) that were funding operations. For instance, in 2023 Coherus’ UDENYCA, CIMERLI, and YUSIMRY products generated substantial sales (investors.coherus.com) before being sold off. The question remains whether Coherus can generate equal or greater value from its novel oncology programs than it gave up by selling those assets. So far, the market appears cautious: Coherus’ market cap is lower than the aggregate deal proceeds it received, suggesting investors were happier seeing cash in hand than betting on the replacement strategy. It will take clinical and commercial execution to demonstrate that shedding the biosimilar business was a value-creating move in the long run.

In summary, Coherus Oncology (CHRS) has radically transformed itself, trading near-term revenues for a shot at proprietary oncology drugs. The recent stock offering shores up its finances for this journey, but also exemplifies the cost to shareholders of repeated capital raises. The company’s dividend-less, high-risk profile is typical for a developmental biotech. Going forward, investors shouldn’t miss updates on LOQTORZI’s market performance and pipeline trial results – these will be the key drivers of Coherus’ stock value. With a cleaner balance sheet (debt-free after payoff of the 2026 notes (investors.coherus.com)) and a war chest of cash, Coherus has given itself a fighting chance. However, execution risk is high, and the clock is ticking for its pipeline to prove itself before the cash runs out. The stock remains a speculative play, sensitive to clinical news flow and the company’s ability to turn its oncology ambitions into tangible shareholder returns.

Sources: Coherus press releases, SEC filings, and financial media. All factual statements are backed by the cited references.

For informational purposes only; not investment advice.